• Shafqut Ali
  • Samia Iram


Background: Hepatitis C is major emerging challenge for pathologists and treating physicians allover the world. Already 10 million Pakistani population has become anti-HCV positive. It is notonly affecting hepatobiliary system but with passage of time research is revealing that Hepatitis Cis going to involve almost every organ of the body. With timely diagnosis and treatment, millionsof patients can be saved from morbidity and mortality. The nation has to sacrifice initial economicallocations to avoid later millions of mortalities and greater economic losses on affected patientsand to support their families. The objective of this study was to evaluate effectiveness of combinetherapy of Hepatitis C in local population of Pakistan. Methods: This case series study was doneat CMH Okara, Kohat, Abbottabad, and PAF Hospital, Shorkot from August 2000 to August2009. All 1,000 patients from 10 to 60 years of age, confirmed anti-HCV Positive by ELISA andPCR Positive for HCV RNA, were subjected to Interferon alpha-2b and Ribavirin therapy forsimilar period of time. Response and adverse affects were observed by clinical examination, bloodcomplete picture including platelet count and ALT fortnightly. PCR for HCV RNA and ultrasoundabdomen (hepatobilliary system) was done quarterly during treatment and 6 monthly for 2 yearsafter treatment to review the sustained response and relapse. Results: Over all cure rate after 2years was 855 (85.5%) excluding the 50 (5%) of initial resistant to one year treatment and 95(9.5%) re-treated relapse cases. One hundred and forty-five (14.5%) patients were found to beresistant to treatment. Conclusion: Hepatitis C must be treated timely after proper diagnosis.Interferon and Ribavirin combination have shown high ‘cure’ rate in Hepatitis C. In spite of highcure rate of 85.5% with timely and proper treatment, low socio-economic status is a majorproblem for poor individuals to get treatment. Preventive aspect must be strictly followed andimplemented.Keywords: HCV, Anti-HCV, PCR, ALT, ELISA, Interferon alpha-2b, Ribavirin, Adverse effects


Alan Francescus. HCV Education and Support: A Brief

Historyof Hepatitis C (Fact Sheet) 2006. Available at:


Aach RD, Steven CE, Hollinger FB, Mobley JW, Petersm DA,

Taylor PE, et al. Identification anti-HCV by first and second

generation of ELISA Assay, N Eng J Med 1991;325;1325–9.

Bukh J, Purcee RH, Millar RH. Importance of primer selection

for the detection of hepatitis C virus RNA with the polymerase

chain reaction assay. Proc Natl Acad Sci USA 1992;89:187–91.

Raja NS, Janjua KA. Epidemiology of hepatitis C virus

infection in Pakistan. J Microbiol immunol infec 2008;41:4–8.

Crowe J, Doyle C Fielding JF, Holloway H, Keegan M,

Kelleher D, et al. Presentation of hepatitis C in a unique

uniform cohort 17 years from inoculation (abstr)

Gastroenterology 1995;108(Suppl 3):A1054.

Misiani R, Bellavita P, Fenilid, Dorelli G, Marchesi D,

Massuzza M, et al. Hepatitis C in patients with essential mixed

cryoglubinaemia. Ann Intern Med 1992;117:573–7.

ForgionS, Pipeperno A, Cappellini MD, Sampietro M,

Fracanzani AL Romano R, et al. Hepatitis C virus and

porphyria cutanea tarda, evidence of a strong association,

Hepatology 1992;16:1322–6.

Johnson RJ, Gretch DC, Yamabe H, HartsJ, Bacchi CE, Hart

Well P, et al. Membranoproliferative glomerulonephritis

associated with Hepatitis C virus infection. N Engl J Med


Horikoshi S, Okada T ; Shirato I; Inokuchi S, Ohmuro H,

Tomino Y, et al. Diffuse proliferative glomerulonephritis with

hepatitis C virus-like particles in paramesangial dense deposits

J Ayub Med Coll Abbottabad 2009;21(4)

in a patient with chronic hepatitis C virus hepatitis. Nephron


Haddad J, Deny P, Munz-Gotheil C, Ambrosini J, Trinchet JC,

Pateron D, et al. Lymphocytic Sialadenitis of Söjgren’s

Syndrome associated with chronic Hepatitis C virus in liver

diseases. Lancet 1992;339:321–3.

Wpawlotsky JM, Ben Yahia M, Andre C, Voison MC, Intrator

L, Roudot-Thorvaval F, et al. Immunological disorders, in

hepatitis C virus in chronic active hepatitis, a prospective case

control study. Hepatology 1994;19:841–8.

Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier

P, et al. High prevalence of thyroid auto-antibodies in

prospective series of patient with chronic hepatitis C before

interferon therapy. Hematology 1993;18:253–7.

Jubert C, Pawlostsky JM, Poujet F, Amdre C, de Forges L,

Bretagne S, et al. Lichen planus and hepatitis C virus related

chronic active hepatitis. Arch Dermatol 1994;130:37–6.

Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi

T, et al. Idiopathic pulmonary fibrosis and prevalence of serum

anti-bodies to hepatitis C virus. Am Rev Respir Dis


Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA.

Mooren-type hepatitis C virus-associated corneal ulceration.

Ophthalmology 1994;101:736–45.

Scotto G, Fazio V, Tantimanaco G. Pilot study of a short

course of ribavirin and alpha interferon in the treatment of

chronic active hepatitis C not responding to alpha interferon

alone. Ital J Gastroentrol 1996;28(9):505–11.

Kryczk W, Zarebsk-Michaluk D, Chrapek M. Assessment of

selected clinical factors as predictors of response to combined

interferon alpha plus ribavirin therapy among patients with

chronic hepatitis C. Med Sci Monit. 2003;9(Suppl 3):32–5.

McHutchison JG, Povnard T. Combination therapy with

interferon plus ribavirin for the initial treatment of chronic

hepatitis C. Semin Liver Dis 1999;13(3):353.

Painko S, McHutchison JG. Treatment of hepatitis C with

interferon and ribavirin. J Gastroentrol Hepatol 2000;15:581–6.



Most read articles by the same author(s)